Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

Cathomas, Richard, Lorch, Anja, Bruins, Harman M., Compérat, Eva M., Cowan, Nigel C., Efstathiou, Jason A., Fietkau, Rainer, Gakis, Georgios, Hernández, Virginia, Espinós, Estefania Linares, Neuzillet, Yann, Ribal, Maria J., Rouanne, Matthieu, Thalmann, George N., van der Heijden, Antoine G., Veskimäe, Erik, Alfred Witjes, J., Milowsky, Matthew I.·2022·European Urology

Abstract

CONTEXT Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution. OBJECTIVE This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma. EVIDENCE ACQUISITION A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. EVIDENCE SYNTHESIS Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations. CONCLUSIONS This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice. PATIENT SUMMARY In recent years, several new treatment options have been introduced for patients with metastatic urothelial cancer (including bladder cancer and cancer of the upper urinary tract and urethra). These include immunotherapy and targeted treatments. This updated guideline informs clinicians and patients about optimal tailoring of treatment of affected patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2021.09.026

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 295

Metadata

Authors
Cathomas, R., Lorch, A., Bruins, H. M., Compérat, E. M., Cowan, N. C., Efstathiou, J. A., Fietkau, R., Gakis, G., Hernández, V., Espinós, E. L., Neuzillet, Y., Ribal, M. J., Rouanne, M., Thalmann, G. N., van der Heijden, A. G., Veskimäe, E., Alfred Witjes, J., & Milowsky, M. I.
Venue
European Urology
Publisher
Elsevier BV
Published
2022-01
Volume
81
Issue
1
Pages
95-103
ISSN
0302-2838 (ISSN-L)
OpenAlex
W3209393335
Cited by
295
References
52
FWCI
49.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. https://app.cochat.ai/papers/10.1016/j.eururo.2021.09.026
The paper
Cathomas, R., Lorch, A., Bruins, H. M., Compérat, E. M., Cowan, N. C., Efstathiou, J. A., Fietkau, R., Gakis, G., Hernández, V., Espinós, E. L., Neuzillet, Y., Ribal, M. J., Rouanne, M., Thalmann, G. N., van der Heijden, A. G., Veskimäe, E., Alfred Witjes, J., & Milowsky, M. I. (2022). The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology. https://doi.org/10.1016/j.eururo.2021.09.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.